Request Trial
shutterstock_1119823829_sureeporn_teerasatean
Sureeporn Teerasatean / Shutterstock.com
9 October 2019PharmaSarah Morgan

CMA alleges collusion allowed 1,800% hike in Aspen drug pricing

African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority (CMA).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Novartis defeats Orange Book challenge but suffers EU setback
24 September 2026   An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.
Pharma
Behind the case: How Novartis defended its blockbuster Entresto in the UK
22 September 2026   After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.
Pharma
Non-profit sues Cambrex over anticancer drug manufacturing trade secrets
17 September 2026   Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

Novartis defeats Orange Book challenge but suffers EU setback
New UK High Court judge named as replacement for Justice Meade
US firm hires litigation pro whose clients include Pfizer, Medtronic
Behind the case: How Novartis defended its blockbuster Entresto in the UK
Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight
Benesch adds former McDermott IP practice head
Leading European patent litigator to join Carpmaels & Ransford
CIPA Congress: Sustainability is essential for the profession and the planet